Nutriband Inc. (NTRB) AI Stock Analysis

Nutriband Inc. specializes in the development of a diverse portfolio of transdermal pharmaceutical products designed to address various medical needs. Its primary innovation is AVERSA fentanyl, an extended-release transdermal system incorporating abuse-deterrent technology for chronic pain management. The company is also advancing additional transdermal therapies, including AVERSA buprenorphine, AVERSA methylphenidate for attention deficit hyperactivity disorder, exenatide for type 2 diabetes management, and follicle stimulating hormone for infertility treatment. Furthermore, Nutriband has entered into a strategic license agreement with Rambam Med-Tech Ltd. to develop the RAMBAM Closed System Transfer Devices, broadening its capabilities in medical delivery technologies.

Nutriband expanded annual revenue from $1.4M in FY2022 to $2.1M in FY2023, reflecting revenue growth of 46.2%. Revenue remained flat at $2.1M in FY2024 and FY2025 before declining 4.8% to $2.0M in FY2026. Gross margin fell from 35.5% in FY2022 to 27.8% in FY2026, while operating margin deteriorated to -408.4%. Annual net income was -$8.2M in FY2026, resulting in an eps of -$2.60. For the trailing twelve months ended July 31, 2026, revenue stood at $1.6M with quarterly revenue growth falling 29.7% year-over-year.

As of July 31, 2026, Nutriband held $3.4M in cash and short-term investments against total debt of $194,620, resulting in net cash of $3.2M. The company maintains a current ratio of 4.21 and a debt-to-equity ratio of 0.04. Free cash flow was -$5.1M in FY2026, driven by operating cash flow of -$5.1M and capital expenditures of $5,320. Additionally, the company increased its share count, with share count change over 5 years reaching 60.2%.

Nutriband trades at an enterprise value of $86.1M and a market cap of $75.6M. Its price-to-sales multiple is 46.7x, and its forward P/E is 370.4x, both standing well above the median of its US-listed Healthcare peers, which post a price-to-sales of 4.1x and a forward P/E of 17.3x. Over the past year, NTRB delivered a return of -19.2%, trailing the S&P 500 benchmark return of 16.8%, though its return year-to-date stands at 37.0%.

Wall Street coverage includes 1 Strong Buy rating, 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The mean price target is $15.00, representing an upside of 141.2% versus the last close of $6.22 on October 16, 2026. For the current fiscal year ending January 31, 2027, the analyst revenue estimate is $0. Nutriband has beaten earnings per share estimates in 3 of the last 4 quarters, and its next earnings date is December 9, 2026.

This page is an AI-written research summary of Nutriband Inc. (NTRB). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NTRB income statement, NTRB balance sheet, NTRB key metrics, NTRB analyst forecast, NTRB chart. See the NTRB stock overview for the latest quote and news.